Yet another class action lawsuit has been filed against AbbVie, maker of the brand-name adalimumab, Humira. The latest suit, brought by the mayor and city council of Baltimore, Maryland, on behalf of themselves and others similarly situated, alleges that, absent AbbVie’s conduct, biosimilar adalimumab could have been available in the United States as early as 2016. It also alleges that biosimilar developer Amgen was paid by AbbVie to delay its marketing of a biosimilar adalimumab.
Yet another class action lawsuit has been filed against AbbVie, maker of the brand-name adalimumab, Humira. The latest suit, brought by the mayor and city council of Baltimore, Maryland, on behalf of themselves and others similarly situated, alleges that, absent AbbVie’s conduct, biosimilar adalimumab could have been available in the United States as early as 2016. It also alleges that biosimilar developer Amgen was paid by AbbVie to delay its marketing of a biosimilar adalimumab.
The complaint, filed on March 22, 2019, in the Northern District of Illinois, claims that AbbVie established a thicket of patents, some with clear deficiencies, to ward off biosimilar competition and allow the brand-name Humira to “command supra-competitive prices.”
The complaint also states that AbbVie paid Amgen by awarding the biosimilar developer de facto market exclusivity by giving the company the first market entry date—January 2023—for its biosimilar, while AbbVie negotiated later marketing dates for other biosimilar products. “Amgen, thus, will have [5] months as the only biosimilar on the market, enabling it to charge higher prices and realize hundreds of millions of dollars in higher profits than it would if it faced competition during this period,” reads the complaint.
According to the suit, while Amgen was not entitled to any period of market exclusivity as a first biosimilar under the Biologics Price Competition and Innovation Act (unlike the Hatch-Waxman Act’s 180-day exclusivity period for first generics), the settlement that Amgen entered into with AbbVie “gave Amgen precisely that. AbbVie agreed not to settle with any other manufacturers on terms that would let them enter the market at the same time as Amgen, or for [5] months thereafter.”
Baltimore claims that the overcharges to Humira that result from the alleged conduct of the 2 drug makers are traceable through the pharmaceutical distribution chain to the city and to other end payers, and asks that the court award damages of 3 times the amount of the overcharges. The complaint also asks for injunctive relief “to stop AbbVie’s unlawful conduct.”
In a statement, Baltimore’s City Solicitor, Andre M. Davis, JD, said, “When big pharma violates the law and engages in schemes to overcharge Baltimore, we will pursue legal recourse to recover millions of taxpayer dollars. Our resources are needed for essential services for our people and to keep taxes down. Tax payer dollars should not go to unjustly enrich large corporations.”
The lawsuit is the latest in a spate of complaints against AbbVie; in September 2018, the State of California filed suit alleging that the company provided kickbacks to healthcare providers throughout the state to encourage them to prescribe its brand-name Humira and that it used a network of registered nurses to mislead patients about the risks associated with the drug. Then, last month, labor union United Food and Commercial Workers Local 1500 filed a class action lawsuit against AbbVie over its alleged patent thicket and alleged collusion with biosimilar developers to divide the market for adalimumab between Europe and the United States.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.